New research findings from the ENZARAD study (ANZUP 1303), led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) in collaboration with the University of Sydney NHMRC Clinical Trials Centre (CTC), were presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.1
Professor Ian Davis, Medical Oncologist and Chair of ANZUP, said, “Our team is excited to share the results of our international ENZARAD study. ENZARAD provides useful practical guidance FOR treatment of high-risk localised and locally advanced prostate cancer, clarifying and redefining how those affected should approach the treatment of this condition.”
The findings provide strong evidence that for most patients, it is not necessary to add a newer androgen receptor inhibitor, enzalutamide, to the standard of care (top-quality radiotherapy with testosterone-lowering therapy, otherwise called ADT). However, ENZARAD showed the benefit of the addition of enzalutamide for people at the highest risk of recurrence or spread of the cancer. The addition of enzalutamide improved metastasis-free survival outcomes for patients with known or suspected pelvic lymph node involvement or other patients where a decision was made that they should have more extensive radiation treatment.1
“This is a significant step forward in identifying who benefits most from intensified treatment, delivering more precise and more effective care tailored to each patient’s needs, while also identifying those who might not need additional treatment and who could avoid unnecessary side effects from overtreatment. Ongoing research will help us further refine which patients without visible lymph node involvement may also gain from this approach.”
The phase 3 ENZARAD trial enrolled 802 participants across 69 sites in Australia, the UK, Ireland, the USA, New Zealand, Belgium, Spain, Austria, and Slovenia.
Prostate cancer remains the most diagnosed cancer among Australians. 2 In 2025, there are expected to be around 28,900 prostate cancer cases diagnosed and 4,000 deaths in Australia. In 2024, prostate cancer was responsible for around 42,000 years of life lost and around 16,000 years lived with a disability in Australia. 2,3 By 2040, it is predicted that there will be 372,000 people living with prostate cancer in Australia, representing the greatest number of people diagnosed with any single cancer.4
Australian and New Zealand Urogenital and Prostate Cancer Trials Group CEO, Samantha Oakes said, “Our mission at ANZUP is to improve the lives of people affected by bladder, kidney, testicular, penile and prostate cancers towards our vision of living life without fear of cancer, as the leading non-for-profit research charity funding multidisciplinary collaborative clinical trials for these ‘Below the Belt’ cancers. Since our inception in 2008, ANZUP has led 35 Below the Belt cancer trials across 772 global sites, providing over 10,000 participants access to innovative clinical trials.”
“We are proud to showcase our Australian-led global study on an international stage. The ENZARAD trial is a powerful example of how collaborative, patient-centred research can lead to more personalised and effective cancer care.”
Source: ANZUP. To learn more about ANZUP’s mission to improve the lives of those affected by bladder, kidney, testicular, penile, and prostate cancers, visit anzup.org.au.
